Literature DB >> 8824348

Automated imaging and quantitation of tumor cells and CFU-GM colonies in microcapillary cultures: toward therapeutic index-based drug screening.

M J Murphy1, F Fushimi, R E Parchment, E Barberá-Guillem.   

Abstract

Human colony forming units (CFUs) from both malignant and hematopoietic tissues can be assayed in vitro in microcapillary cultures, an alternative cloning system to the Petri dish methodology. For technical reasons, microcapillary culture may be ideally suited for new drug screening by therapeutic index. To achieve the high output required by screening programs, automated quantitation of CFUs is required. Toward this end, this paper reports the development of a prototype CapScan, an image analysis system that uses a novel axial laser illumination system to detect tumor cell colonies and, with technical modifications, CFU-granulocyte-macrophage (CFU-GM) colonies in microcapillary cultures. As currently configured, the CapScan can quantify colonies grown in a rack of 18 microcapillary cultures in 30 minutes or less. The sensitivity and detection specificity of tumor cell colonies is >90% with a coefficient of variance of 5-40%, dependent upon colony number. Over a range of colony numbers, CapScan and manual colony counts showed a linear correlation > -0.9, and yielded identical results in assays of doxorubicin inhibition of clonogenic P388 cells. As an additional advantage, the growth kinetics of individual colonies can also be monitored with the CapScan, making distinctions between cytotoxic and cytostatic drugs possible; colonies of freshly isolated human tumor cells can also be quantified. Thus, a microcapillary-based human tumor cloning assay that tests for resistance and/or sensitivity to chemotherapeutic agents may be useful in drug development programs and may also facilitate the development of chemotherapy for individual patient tumors, especially when tumor availability is limited.

Entities:  

Mesh:

Year:  1996        PMID: 8824348     DOI: 10.1007/bf00873136

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  25 in total

1.  Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures.

Authors:  D H Kern; L M Weisenthal
Journal:  J Natl Cancer Inst       Date:  1990-04-04       Impact factor: 13.506

2.  Experimental studies of the biology of human small cell lung cancer.

Authors:  D N Carney; L Broder; M Edelstein; A F Gazdar; M Hansen; K Havemann; M J Matthews; G D Sorenson; L Videløv
Journal:  Cancer Treat Rep       Date:  1983-01

3.  Recombinant human GM-CSF significantly enhances the cytostatic activity of cell cycle specific anti-leukaemic drugs in HL-60 human myeloid leukaemia clonogenic cells in a capillary clonogenic micro-assay.

Authors:  H T Hassan; A Veit; H R Maurer
Journal:  Anticancer Res       Date:  1991 Jan-Feb       Impact factor: 2.480

4.  Combination of flavone acetic acid (FAA) with adriamycin, cis-platinum and difluoromethylornithine (DFMO) in vitro against human colon cancer cells.

Authors:  S S Neelam; A Bernabei; C Freedland; R Thompson; T H Corbett; G D Luk
Journal:  Invest New Drugs       Date:  1990-08       Impact factor: 3.850

5.  New colorimetric cytotoxicity assay for anticancer-drug screening.

Authors:  P Skehan; R Storeng; D Scudiero; A Monks; J McMahon; D Vistica; J T Warren; H Bokesch; S Kenney; M R Boyd
Journal:  J Natl Cancer Inst       Date:  1990-07-04       Impact factor: 13.506

6.  Effects of L-phenylalanine mustard and L-buthionine sulfoximine on murine and human hematopoietic progenitor cells in vitro.

Authors:  D L Du; D A Volpe; C K Grieshaber; M J Murphy
Journal:  Cancer Res       Date:  1990-07-01       Impact factor: 12.701

7.  Capillary cloning of primary human tumor cells: assay miniaturization for drug efficacy testing.

Authors:  X E Peng; G Z Chen; Y F Lu; M J Murphy
Journal:  Int J Cell Cloning       Date:  1989-09

8.  Optimization and characterization of the capillary human tumor clonogenic cell assay.

Authors:  F Ali-Osman; P A Beltz
Journal:  Cancer Res       Date:  1988-02-01       Impact factor: 12.701

9.  In vitro myelotoxicity of 2',3'-dideoxynucleosides on human hematopoietic progenitor cells.

Authors:  D L Du; D A Volpe; C K Grieshaber; M J Murphy
Journal:  Exp Hematol       Date:  1990-08       Impact factor: 3.084

Review 10.  Therapeutic index: a vital component in selection of anticancer agents for clinical trial.

Authors:  J A Double; M C Bibby
Journal:  J Natl Cancer Inst       Date:  1989-07-05       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.